vTv Therapeutics (VTVT) Competitors $17.15 -0.06 (-0.35%) Closing price 04:00 PM EasternExtended Trading$17.32 +0.18 (+1.02%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTVT vs. INMB, TVGN, VYGR, ELDN, INBX, ACIU, DMAC, BTMD, SOPH, and NGNEShould you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include INmune Bio (INMB), Tevogen Bio (TVGN), Voyager Therapeutics (VYGR), Eledon Pharmaceuticals (ELDN), Inhibrx (INBX), AC Immune (ACIU), DiaMedica Therapeutics (DMAC), biote (BTMD), SOPHiA GENETICS (SOPH), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. vTv Therapeutics vs. INmune Bio Tevogen Bio Voyager Therapeutics Eledon Pharmaceuticals Inhibrx AC Immune DiaMedica Therapeutics biote SOPHiA GENETICS Neurogene INmune Bio (NASDAQ:INMB) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk, community ranking and earnings. Do institutionals & insiders have more ownership in INMB or VTVT? 12.7% of INmune Bio shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 35.2% of INmune Bio shares are held by insiders. Comparatively, 1.3% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, INMB or VTVT? INmune Bio has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Does the media favor INMB or VTVT? In the previous week, vTv Therapeutics had 4 more articles in the media than INmune Bio. MarketBeat recorded 6 mentions for vTv Therapeutics and 2 mentions for INmune Bio. vTv Therapeutics' average media sentiment score of 1.09 beat INmune Bio's score of 0.94 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive vTv Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer INMB or VTVT? vTv Therapeutics received 208 more outperform votes than INmune Bio when rated by MarketBeat users. However, 76.60% of users gave INmune Bio an outperform vote while only 57.14% of users gave vTv Therapeutics an outperform vote. CompanyUnderperformOutperformINmune BioOutperform Votes14476.60% Underperform Votes4423.40% vTv TherapeuticsOutperform Votes35257.14% Underperform Votes26442.86% Do analysts rate INMB or VTVT? INmune Bio presently has a consensus target price of $22.80, indicating a potential upside of 207.28%. vTv Therapeutics has a consensus target price of $35.00, indicating a potential upside of 104.80%. Given INmune Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe INmune Bio is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, INMB or VTVT? vTv Therapeutics has higher revenue and earnings than INmune Bio. vTv Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$42K4,697.74-$30.01M-$2.18-3.40vTv Therapeutics$1.02M53.61-$20.25M-$3.41-5.01 Is INMB or VTVT more profitable? INmune Bio's return on equity of -117.48% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -117.48% -78.96% vTv Therapeutics N/A -184.64%-47.29% SummaryINmune Bio beats vTv Therapeutics on 11 of the 18 factors compared between the two stocks. Remove Ads Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTVT vs. The Competition Export to ExcelMetricvTv TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.52M$6.91B$5.63B$8.11BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-3.777.2124.5119.02Price / Sales53.61225.69383.3192.07Price / CashN/A65.6738.1634.64Price / Book-1.846.506.954.34Net Income-$20.25M$142.41M$3.20B$247.23M7 Day Performance-2.90%-2.94%-2.34%-0.62%1 Month Performance-7.04%-4.45%3.04%-3.84%1 Year Performance-28.19%-8.40%11.14%1.70% vTv Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTVTvTv Therapeutics2.0382 of 5 stars$17.15-0.3%$35.00+104.1%-25.5%$54.71M$1.02M-3.799Earnings ReportAnalyst ForecastPositive NewsINMBINmune Bio1.9262 of 5 stars$8.30+2.2%$22.80+174.7%-34.9%$220.71M$42,000.00-3.8110News CoveragePositive NewsTVGNTevogen Bio3.2272 of 5 stars$1.24+8.8%$7.10+472.6%-68.8%$217.06MN/A0.003VYGRVoyager Therapeutics4.6514 of 5 stars$3.91+0.8%$14.86+280.0%-63.7%$215.86M$80.00M5.51100ELDNEledon Pharmaceuticals1.9417 of 5 stars$3.61+2.8%$12.50+246.3%+59.0%$215.66MN/A-1.8010Earnings ReportAnalyst RevisionNews CoveragePositive NewsINBXInhibrx1.8833 of 5 stars$14.72+2.6%N/A-59.4%$213.09M$200,000.000.00166Short Interest ↓News CoveragePositive NewsACIUAC Immune2.6444 of 5 stars$2.12+1.0%$12.00+466.0%-29.9%$212.87M$27.31M-4.61140Short Interest ↑Gap UpDMACDiaMedica Therapeutics1.661 of 5 stars$4.95-0.6%$8.00+61.6%+50.0%$212.14MN/A-8.8420BTMDbiote3.5847 of 5 stars$3.90+1.0%$8.00+105.1%-36.9%$211.91M$197.19M15.00194Gap UpSOPHSOPHiA GENETICS2.6634 of 5 stars$3.12+3.3%$6.80+117.9%-25.2%$208.06M$65.17M-2.86520Short Interest ↓NGNENeurogene1.9834 of 5 stars$13.96-1.8%$60.80+335.5%-67.4%$207.38M$925,000.000.0090Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Remove Ads Related Companies and Tools Related Companies INMB Alternatives TVGN Alternatives VYGR Alternatives ELDN Alternatives INBX Alternatives ACIU Alternatives DMAC Alternatives BTMD Alternatives SOPH Alternatives NGNE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTVT) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
